Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658728 | 0.84 | HTT (0.67) | HTTPTGS1PTGS2HPGDTSHR | |
| SCHEMBL23122211 | 0.79 | HTT (0.61) | HTTPTGS1PTGS2HPGDTSHR | |
| SCHEMBL16133046 | 0.77 | PTGS1 (0.51) | HTTPTGS1PTGS2HPGDTSHR | |
| SCHEMBL764726 | 0.75 | PTGS1 (0.56) | HTTPTGS1PTGS2HPGDTSHR | |
| SCHEMBL13645937 | 0.75 | HPGD (0.67) | HTTHPGDALDH1A1LMNAKMT2A | |
| SCHEMBL27846331 | 0.73 | PTGS1 (0.78) | HTTPTGS1PTGS2HPGDTSHR | |
| SCHEMBL1131637 | 0.73 | CYP1A2 (0.69) | HTTHPGDTSHRALDH1A1LMNA | |
| SCHEMBL17753763 | 0.73 | PTGS1 (0.54) | HTTPTGS1PTGS2HPGDTSHR | |
| SCHEMBL29074397 | 0.72 | HTT (0.53) | HTTPTGS1PTGS2HPGDTSHR | |
| SCHEMBL1056332 | 0.72 | PTGS1 (1.00) | HTTPTGS1PTGS2HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | HTT 832/4885PTGS1 1978/4885PTGS2 3107/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | HTT 832/4885PTGS1 1978/4885PTGS2 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.